Innate Pharma S.A.

Innate Pharma is the small-cap French biotech that just signed a strategic partnership with Sobi for lacutamab in T-cell lymphoma — a deal worth up to $465M in eligible milestones. Up 15% year-over-year with fresh sell-side upgrades landing.

• The Sobi partnership is the specific transformational catalyst: up to $465M in eligible milestone payments plus royalties transforms Innate from a clinical-stage biotech into a specific commercial-partnership-secured company — the type of deal that essentially secures Phase 3 financing without dilution.
• BTIG raising the price target to $9 from $8 is the specific analyst validation: sell-side moving PTs in the wake of the deal reflects underwriting the milestone math, and the current $2.5 price gives meaningful upside to the target.
• The Q4 print is essentially placeholder pre-deal: negative revenue reporting on Q4 reflects the clinical-stage cost structure, and the balance sheet math changes materially now that Sobi is funding the Phase 3 path.
• The technical setup shows the deal-driven reaction: shares sit 47% above the 200-day and 89% of the 52-week range on the Sobi news — the specific pattern of a small-cap biotech that just secured its clinical-development runway.

Coming into Sept 17 earnings, the tape needs specific Phase 3 lacutamab trial-timing commentary, Sobi partnership execution updates, and any additional pipeline disclosures on the T-cell lymphoma program. A clean update plus favorable trial timing extends the trend toward the BTIG $9 PT; any Sobi-partnership execution friction is what would compress the deal-driven rally from current levels.